We are live on ! Find out more
OTLK icon

Outlook Therapeutics

75 hedge funds and large institutions have $25.3M invested in Outlook Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

3% more funds holding

Funds holding: 7375 (+2)

0.02% less ownership

Funds ownership: 0.57%0.55% (-0.02%)

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

44% less capital invested

Capital invested by funds: $45.3M → $25.3M (-$20.1M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
75
Holders Change
+2
Holders Change %
+2.74%
% of All Funds
1.26%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
15
Increased
23
Reduced
24
Closed
12
Calls
Puts
Net Calls
Net Calls Change

OTLK Hedge Fund Activity: Q2 2022 in Review

75 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2022, worth a combined $25.3M — down 44% from $45.3M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new OTLK positions and 12 closed out — a net gain of 3 holders — while 23 added to existing stakes and 24 trimmed.

The largest buyer was BlackRock, adding an estimated $396K. The largest seller was Renaissance Technologies, cutting an estimated $744K.

  • 75 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2022, up from 73 in Q1 2022.
  • Funds reported $25.3M of Outlook Therapeutics stock for Q2 2022, down 44% quarter-over-quarter.
  • 15 funds opened new Outlook Therapeutics positions in Q2 2022 and 12 closed out, a net change of +3 holders.
  • The largest Outlook Therapeutics buyer in Q2 2022 was BlackRock, an estimated $396K added.
  • The largest Outlook Therapeutics seller in Q2 2022 was Renaissance Technologies, an estimated $744K sold.

Based on aggregated 13F filings for Q2 2022.